- Details
- Description
-
Packaging Size30c/bottle
-
Strength100mg
-
CompositonLarotrectinib
-
TreatmentNTRK gene fusion-positive solid tumors
-
FormCapsule
-
BrandLuciLaro
-
Quantity Unit100mg*30c/bottle
-
ManufacturerLUCIUS PHARMACEUTICAL,Laos PDR
Larotrectinib is a treatment for solid cancers that have a neurotrophic tyrosine receptor kinase (NTRK) gene change. You might have larotrectinib for a solid cancer if: your cancer is locally advanced or advanced (metastatic) surgery to remove the cancer could cause severe health problems.
Solid Tumors
Indicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment
100 mg PO BID
Continue until disease progression or until unacceptable toxicity
Dosage Modifications
Dosage modifications for adverse reactions
-
Body Surface Area (BSA) ≥1 m2
- First occurrence: 75 mg BID
- Second occurrence: 50 mg BID
- Third occurrence: 100 mg qDay
- Unable to tolerate 100 mg qDay: Permanently discontinue
